Objective To evaluate the correlation between hyperuricemia (HUA) and benign prostatic hyperplasia (BPH). Methods A total of 666 elderly male patients, who had been admitted to the West China Hospital for routine physical examination in May, 2010, were included in this study. All the following indexes were collected: blood pressure, waistline, medical history, international prostatic symptom score (IPSS), serum uric acid (UA), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), 2-hour postprandial blood glucose (PBG-2), prostate-specific antigen (PSA), and prostate volume (PV) measured by ultrasound. Patients with higher level of UA more than 420 μmol/L were included into the HUA group (n=151) while the other patients with normal UA (NUA) were in the NUA group (n=515). Both the metabolic and prostate related indexes in the two groups were compared, and the correlation between HUA and each indexes were analyzed using logistic regression model. Results HUA was significantly associated with abdominal obesity (OR=1.575, 95%CI 1.059 to 2.340), hypertriglyceridemia (OR=2.78, 95%CI 1.877 to 4.118), metabolic syndrome (CDS2007) (OR=1.912, 95%CI 1.267 to 2.885), BPH (OR=1.464, 95%CI 1.465 to 1.635) and lower urinary tract symptoms (LUTS) rating (OR=1.782, 95%CI 1.173 to 1.522). Conclusion HUA is correlated with BPH, meanwhile it is highly accompanied with other risk factors of cardioascular diseases. Hereby, comprehensive medical screening should be considered when treating such patients.
Objective To investigate the prevalence of hyperuricemia and the current status as well as differences of cardiovascular risk factors in hyperuricemia patients between urban and rural areas in Chengdu. Methods We randomly sampled 2 032 patients aged from 35 to 70 years age in urban and rural communities, using a questionnaire, physical examination and laboratory tests. Results a) The prevalence of hyperuricemia was 17.77%, which was higher in urban residents (21.38%) than that in rural residents (14.16%). b) The prevalence of hyperuricemia associated with hypercholesterolemia was higher in urban residents (34.10%) than that in rural residents (13.98%); urban women (39.06%) were higher than rural women (16.13%) and urban men (26.97%) were higher than rural men (12.20%). c) The prevalence of hyperuricemia associated with hypertension which was higher in urban residents (58.06%) than that in rural residents (32.64%); urban women (59.38%) were higher than rural women (35.48%) and urban men (56.18%) were higher than rural men (30.49%). d) The prevalence of hyperuricemia associated with impaired glucose tolerance (IGT) in urban women (28.91%) were lower than that in rural women (45.16%). Conclusion Hypercholesterolemia and hypertension are the most commonly seen cardiovascular risk factors accompanied in patients with hyperuricemia in urban areas, which has obviously higher prevalence than in rural areas. IGT is the most commonly seen cardiovascular risk factors accompanied in patients with hyperuricemia among rural women. But in aspects of hyperuricemia associated with impaired fasting glucose (IFG), hypertriglyceridemia, low high-density fetoprotein cholesterol, abdominal obesity and obesity, there is no difference between urban and rural areas.
目的 探讨成都地区高尿酸血症发生的危险因素。 方法 收集2009年10月－2010年4月在四川大学华西医院体检中心进行健康体检的36 639人的临床资料，对资料进行单因素分析和多因素logistic回归分析。 结果 进行健康体检的36 639人，其中男21 175人，女15 464人。高尿酸血症患者5 233例，患病率为14.3%。年龄＞50岁、男性、饮酒、糖尿病、高血压病、甘油三酯增高、低密度脂蛋白增高和血清肌酐水平增高与高尿酸血症的发生有关。Logistic回归分析显示男性（OR=13.300，P=0.000）、饮酒（OR=4.219，P=0.009）、糖尿病（OR=3.609，P=0.024）是发生高尿酸血症独立危险因素。 结论 成都地区高尿酸血症的患病率略高于全国平均水平，临床治疗和护理高尿酸血症的患者时应积极控制与高尿酸血症发生密切相关的危险因素。
Objective To compare the efficacy and safety of benzbromarone vs. allopurinol for primary gout. Methods Searching PubMed, Cochrane Library, EMbase, CNKI, VIP and CBM, randomized controlled trials were collected and the quality of RCTs was evaluated using Cochrane systematic review. Meta-analysis was performed. Results 6 RCTs were included in this study,with a total of 350 patients. Meta-analysis showed that there was no statistical significance in total effective rate between two groups (Pgt;0.05). 4 RCTs were enrolled in comparison of ADR. There was statistical significance between two groups (Plt;0.05). Conclusion There is no significant difference in the efficacy between benzbromarone and allopurinol for the primary gout.But benzbromarone is safe than allopurinol for primary gout .
Objective To assess the effectiveness and safety of irbesartan for hypertensive patients with hyperuricaemia. Methods The databases such as The Cochrane Library (Issue 2, 2010), MEDLINE (by the end of April 2010), SCI (by the end of April 2010), CBM (by the end of April 2010) and CNKI (by the end of April 2010) were searched to collected randomized controlled trails (RCTs) on irbesartan for hypertensive combined with hyperuricaemia. Studies were screened according to the inclusion and exclusion criteria; data were extracted; the methodological quality was evaluated; and meta-analyses were conducted by using RevMan 5.0.0 software. Results Nine studies involving 977 patients were included. The results of meta-analyses showed that compared with the control group, irbesartan was superior in decreasing serum uric acid (SUA) (MD=57.12, 95%CI 16.08 to 98.15, P=0.006); it was similar in controlling blood pressure (Systolic pressure: MD= –0.24, 95%CI –2.19 to 1.71, P=0.81; Diastolic pressure: MD=0.46, 95%CI –1.58 to 2.50, P=0.66), and lower in the incidence rate of adverse reaction (RR=0.07, 95%CI 0.02 to 0.24, P=0.000 1). Conclusion The study suggests that irbesartan is effective and safe to control blood pressure and decrease serum uric acid for hypertensive patients with hyperuricaemia. But because all nine included studies are graded C in quality, the conclusion still needs to be further verified by long-term, large scale and high quality studies.
Objective To study the risk factors of hyperuricemia in patients with mild coronary artery stenosis. Methods The clinical data of 267 patients, who underwent coronary angiography, were collected and classified into the hyperuricemia group (58.5±8.0 years) and the normal control group (57.3±9.9 years). The coronary artery diameter stenosis of all the patients was lower than 50%. Results Elevated levels of body mass index (BMI), serum creatinine, triglyceride, low level of high-density lipoprotein, and history of hypertension or diabetes mellitus were significantly correlated with increased prevalence of hyperuricemia in patients with mild coronary artery stenosis. Multivariate logistic regression models found that the risk factors were diabetes mellitus (OR=1.999, 95%CI 1.087 to 3.678) , BMI (OR=1.110, 95%CI 1.009 to 1.221), hypertriglyceridemia (OR=1.237, 95%CI 1.023 to 1.496), and serum creatinine (OR=1.026, 95%CI 1.008 to 1.045). Conclusion Diabetes mellitus, BMI, hypertriglyceridemia and serum creatinine are independent risk factors of hyperuricemia in patients with mild coronary artery stenosis.
Objective To assess the efficacy and safety Losartan for essential hypertension associated withhyperuricemia. Methods Included randomized controlled trials of Losartan versus Valsartan. Electronic searchconducted in CENTRAL, the Cochrane Library (until 2008, Issue 4), PubMed, EMBASE, Chinese Biomedicine database,Chinese Scientific Journals Full-text Database, and China Journal Full-text Database (until 2008, Issue 10). Two reviewers extracted data independently. RevMan 5.0 software developed by the Cochrane Collaboration was used for Metaanalysis.Results Only 7 trials with 1 136 eligible patients were included in the systematic review. Meta-analysis showedno significant difference in reductions of systolic blood pressure, diastolic blood pressure, and adverse events betweenLosartan and Valsartan groups. However, a significant difference of serum uric acid reduction was observed betweenLosartan and Valsartan group. Losartan play a significant role of decreased serum uric acid levels. Conclusions Based on this systematic review, Losartan is effective and well tolerated in reducing BP and serum uric acid levels. Further large randomized, double blind, placebo controlled trials are needed in long-term safety and efficacy and different subgroups of Losartan.
目的 观察秦绵祛风胶囊对鹌鹑高尿酸血症的影响。 方法 通过喂饲用酵母配制的造模饲料造成鹌鹑高尿酸血症模型，设秦绵祛风胶囊高、中、低3个剂量组并以苯溴马隆为阳性对照，在造模的同时连续灌胃药35 d，检测血中黄嘌呤氧化酶、尿酸、血尿素氮和三酰甘油及粪便中尿酸含量。 结果 模型动物血清中黄嘌呤氧化酶、尿酸和三酰甘油水平及粪便中尿酸含量较正常对照组明显升高。秦绵祛风胶囊各剂量组均可显著降低鹌鹑血清中的尿酸和三酰甘油水平，同时升高粪便中尿酸含量，对血清中黄嘌呤氧化酶活性影响不大。 结论 秦绵祛风胶囊具有降脂降尿酸的功能，其机制可能是通过提高动物排泄尿酸的能力，从而降低血中尿酸的含量。
目的 了解成都地区非酒精性脂肪肝（NAFLD）及高尿酸血症（HUA）患病情况及相关因素。 方法 对2010年9月－2011年3月健康体检的36 000名18岁以上受检者，进行病史采集、体格检查、空腹血糖、血脂、肝功能、肾功能、血尿酸检测以及上腹部彩色多普勒超声检查。 结果 高尿酸血症（HUA）的总患病率为18.17%。NAFLD患者HUA患病率为39.41%，明显高于总患病率（P＜0.01）。NAFLD患者的HUA患病率随体质量指数（BMI）的增加呈递增趋势。BMI、舒张压、甘油三酯、胆固醇、丙氨酸转氨酶、门冬氨酸氨转移酶、谷氨酰转肽酶、血肌酐、胱抑素C均随着血尿酸水平的升高而递增；高密度脂蛋白随着血尿酸水平的升高而递减。 结论 NAFLD及HUA关系密切，且二者与代谢紊乱联系紧密。
目的 探讨不同性别IgA肾病患者合并高尿酸血症的临床及肾脏病理特点。 方法 采用回顾性研究方法，将2008年1月－2010年12月收治的226例经肾活检确诊的原发性IgA肾病患者分为男性高尿酸血症组、男性尿酸正常组、女性高尿酸血症组及女性尿酸正常组4组，统计分析4组的临床指标及病理指标。 结果 高尿酸血症患病率男性（21.7%）高于女性（11.9%），差异有统计学意义（P＜0.01），尿检异常型患病率男性（14.6%）高于女性（4.0%），差异有统计学意义（P＜0.01），女性LeeⅢ级的患病率（7.1%）高于男性（5.8%），差异有统计学意义（P＜0.01）；男性高尿酸血症组的尿素氮高于尿酸正常组（P＜0.05），女性高尿酸血症组的血尿素氮、血肌酐、胱抑素C、舒张压、甘油三酯比尿酸正常者明显增高（P＜0.01），女性高尿酸血症组的高密度脂蛋白明显高于男性组（P ＜0.01）。 结论 高尿酸血症是IgA肾病的危险因素，可导致更严重的肾功能损害及肾脏病理损害，这种影响在不同性别中存在差异。